TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,206,338 | -46.4% | 246,794 | -7.9% | 0.00% | – |
| Q2 2023 | $4,117,479 | -63.2% | 268,065 | -46.1% | 0.00% | -100.0% |
| Q1 2023 | $11,180,364 | +384.1% | 497,126 | +352.7% | 0.00% | – |
| Q4 2022 | $2,309,283 | -41.3% | 109,809 | -31.3% | 0.00% | – |
| Q3 2022 | $3,937,000 | +91.6% | 159,774 | +88.4% | 0.00% | – |
| Q2 2022 | $2,055,000 | -42.5% | 84,806 | -38.9% | 0.00% | – |
| Q1 2022 | $3,575,000 | -70.6% | 138,728 | -64.6% | 0.00% | – |
| Q4 2021 | $12,166,000 | +122.7% | 391,952 | +74.0% | 0.00% | – |
| Q3 2021 | $5,464,000 | +107.8% | 225,289 | +25.0% | 0.00% | – |
| Q2 2021 | $2,629,000 | +0.3% | 180,174 | +71.6% | 0.00% | – |
| Q1 2021 | $2,622,000 | -75.2% | 104,998 | -72.9% | 0.00% | -100.0% |
| Q4 2020 | $10,562,000 | – | 387,528 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |